These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 15213148)

  • 1. Oral vaccination with Brucella melitensis WR201 protects mice against intranasal challenge with virulent Brucella melitensis 16M.
    Izadjoo MJ; Bhattacharjee AK; Paranavitana CM; Hadfield TL; Hoover DL
    Infect Immun; 2004 Jul; 72(7):4031-9. PubMed ID: 15213148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection of mice against brucellosis by vaccination with Brucella melitensis WR201(16MDeltapurEK).
    Hoover DL; Crawford RM; Van De Verg LL; Izadjoo MJ; Bhattacharjee AK; Paranavitana CM; Warren RL; Nikolich MP; Hadfield TL
    Infect Immun; 1999 Nov; 67(11):5877-84. PubMed ID: 10531243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection of BALB/c mice against homologous and heterologous species of Brucella by rough strain vaccines derived from Brucella melitensis and Brucella suis biovar 4.
    Winter AJ; Schurig GG; Boyle SM; Sriranganathan N; Bevins JS; Enright FM; Elzer PH; Kopec JD
    Am J Vet Res; 1996 May; 57(5):677-83. PubMed ID: 8723881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Brucella melitensis B115 as rough-phenotype vaccine against B. melitensis and B. ovis infections.
    Adone R; Francia M; Ciuchini F
    Vaccine; 2008 Sep; 26(38):4913-7. PubMed ID: 18675869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced efficacy of recombinant Brucella abortus RB51 vaccines against B. melitensis infection in mice.
    Vemulapalli R; Contreras A; Sanakkayala N; Sriranganathan N; Boyle SM; Schurig GG
    Vet Microbiol; 2004 Sep; 102(3-4):237-45. PubMed ID: 15327798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A study on the use of male animal models for developing a live vaccine for brucellosis.
    Izadjoo MJ; Mense MG; Bhattacharjee AK; Hadfield TL; Crawford RM; Hoover DL
    Transbound Emerg Dis; 2008 May; 55(3-4):145-51. PubMed ID: 18405337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of protective efficacy of subcutaneous versus intranasal immunization of mice with a Brucella melitensis lipopolysaccharide subunit vaccine.
    Bhattacharjee AK; Izadjoo MJ; Zollinger WD; Nikolich MP; Hoover DL
    Infect Immun; 2006 Oct; 74(10):5820-5. PubMed ID: 16988260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brucella melitensis 16MΔhfq attenuation confers protection against wild-type challenge in BALB/c mice.
    Zhang J; Guo F; Chen C; Li Z; Zhang H; Wang Y; Zhang K; Du G; Li Y; Wang J; Jian T; Wang Z
    Microbiol Immunol; 2013 Jul; 57(7):502-10. PubMed ID: 23647412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective live oral brucellosis vaccines stimulate Th1 and th17 cell responses.
    Clapp B; Skyberg JA; Yang X; Thornburg T; Walters N; Pascual DW
    Infect Immun; 2011 Oct; 79(10):4165-74. PubMed ID: 21768283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the immunogenicity and the protective efficacy in mice of a DNA vaccine encoding SP41 from Brucella melitensis.
    Al-Mariri A; Abbady AQ
    J Infect Dev Ctries; 2013 Apr; 7(4):329-37. PubMed ID: 23592643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nasal immunization with recombinant Brucella melitensis bp26 and trigger factor with cholera toxin reduces B. melitensis colonization.
    Yang X; Walters N; Robison A; Trunkle T; Pascual DW
    Vaccine; 2007 Mar; 25(12):2261-8. PubMed ID: 17239499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant.
    Al-Mariri A; Tibor A; Mertens P; De Bolle X; Michel P; Godefroid J; Walravens K; Letesson JJ
    Infect Immun; 2001 Aug; 69(8):4816-22. PubMed ID: 11447155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection of BALB/c mice against Brucella melitensis 16 M infection induced by vaccination with live Escherchia coli expression Brucella P39 protein.
    Al-Mariri A
    Vaccine; 2010 Feb; 28(7):1766-70. PubMed ID: 20036752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infection.
    Cassataro J; Estein SM; Pasquevich KA; Velikovsky CA; de la Barrera S; Bowden R; Fossati CA; Giambartolomei GH
    Infect Immun; 2005 Dec; 73(12):8079-88. PubMed ID: 16299302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization of mice with recombinant S-adenosyl-L-homocysteine hydrolase protein confers protection against Brucella melitensis infection.
    Yang Y; Yin J; Guo D; Lang X; Wang X
    FEMS Immunol Med Microbiol; 2011 Mar; 61(2):159-67. PubMed ID: 21166726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The candidate vaccine strain Brucella ovis ∆abcBA is protective against Brucella melitensis infection in mice.
    Costa LF; Cabello AL; Batista DFA; Chaki SP; de Figueiredo P; da Paixão TA; Rice-Ficht AC; Ficht TA; Santos RL
    Microbiol Immunol; 2020 Nov; 64(11):730-736. PubMed ID: 32965738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Brucella melitensis M5-90 wboA deletion strain is attenuated and enhances vaccine efficacy.
    Li ZQ; Shi JX; Fu WD; Zhang Y; Zhang J; Wang Z; Li TS; Chen CF; Guo F; Zhang H
    Mol Immunol; 2015 Aug; 66(2):276-83. PubMed ID: 25899866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy evaluation of live Escherichia coli expression Brucella P39 protein combined with CpG oligodeoxynucleotides vaccine against Brucella melitensis 16M, in BALB/c mice.
    Al-Mariri A; Mahmoud NH; Hammoud R
    Biologicals; 2012 Mar; 40(2):140-5. PubMed ID: 22296786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological responses and protective efficacy against Brucella melitensis induced by bp26 and omp31 B. melitensis Rev.1 deletion mutants in sheep.
    Jacques I; Verger JM; Laroucau K; Grayon M; Vizcaino N; Peix A; Cortade F; Carreras F; Guilloteau LA
    Vaccine; 2007 Jan; 25(5):794-805. PubMed ID: 17070627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD8 knockout mice are protected from challenge by vaccination with WR201, a live attenuated mutant of Brucella melitensis.
    Yingst SL; Izadjoo M; Hoover DL
    Clin Dev Immunol; 2013; 2013():686919. PubMed ID: 24288554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.